{'fraction_non_alphanumeric': 0.02826585179526356, 'fraction_numerical': 0.02826585179526356, 'mean_word_length': 4.927601809954751, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 1, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Association of Ki-67 Expression and Response of Neoadjuvant Chemotherapy in Invasive Breast Cancer Patients in Bandung

Objective : To analyze the association of Ki-67 expression and response of neoadjuvant chemotherapy in patients with invasive breast cancer.  Methods : A retrospective observational study on the association of Ki-67 expression and response of neoadjuvant chemotherapy in patients with invasive breast cancer was conducted. This study included twenty-five female patients with invasive breast cancer who met the inclusion criteria. Parameters analyzed were age, tumor size, and immunohistochemical expression of Ki-67. Size of the tumor at pre- and post-neoadjuvant chemotherapy were obtained in cm3 and compared between 3 groups of Ki-67 expression levels. One way ANOVA was used to perform the statistical analysis.  Results : A significant difference in changes of tumor size for Ki-67 level >20% compared to 20%.  Conclusions :  Low to modest expression of Ki-67 was a better biomarker to predict the response of neoadjuvant chemotherapy in patients with invasive breast cancer compared to high expression of Ki-67. However, the cut-off value of 20% could be ideal to predict the outcome of neoadjuvant chemotherapy in patients with invasive breast cancer. DOI: 10.15850/ijihs.v6n2.1374